Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

- New Progression-Free Survival Data Support Picoplatin in Combination with Docetaxel/Prednisone as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer -

- Results To Be Presented at the American Society of Clinical Oncology's 2009 Genitourinary Cancers Symposium -

SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of new efficacy and safety data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone as first-line therapy for metastatic castration-resistant prostate cancer (CRPC). Results showed that the combination is active as first-line therapy for metastatic CRPC (also known as hormone-refractory prostate cancer) as demonstrated by prostate specific antigen (PSA) levels, time to PSA progression and radiologic response rates. Results also continue to show that picoplatin can be safely administered with full-doses of docetaxel and prednisone, the standard treatment for CRPC.

"The time to PSA progression data along with high rates of PSA response in this ongoing Phase 2 trial are encouraging and suggest potential clinical benefit when picoplatin is combined with docetaxel and prednisone as a first-line therapy for patients with CRPC," said William K. Oh, M.D., clinical director of the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and associate professor, Harvard Medical School. "While awaiting final data from this trial, I believe that the updated results reported to date warrant consideration of a Phase 3 clinical trial to compare picoplatin with docetaxel and prednisone to docetaxel and prednisone alone in metastatic CRPC patients, a group of men with
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... (PRWEB) May 16, 2013 The ... by Global Cooling, Inc., Athens, OH, USA, won the ... by the International Society for Biological and Environmental Repositories ... award, given to one product annually, recognizes the company’s ... ultra-low temperature freezer. The award was presented to ...
(Date:5/16/2013)... 16, 2013 A new selection ... from Cole-Parmer is designed to meet the dynamic ... , The new Cole-Parmer® MS-3400 Centrifuges ... the lab. They ensure a powerful and complete ... separation. Their standard four-place swinging buckets hold 50-mL ...
(Date:5/16/2013)... SAN DIEGO , May 16, 2013  The ... the Association of Bioscience Financial Officers (ABFO) 2013 National Conference, ... will be held May 28-31 at the Hilton San ... finishing touches on this year,s conference and want to ... opportunity to attend," said Brandi Roberts ...
(Date:5/16/2013)... , May 16, 2013 /PRNewswire/ ... market research report is available in ... Competitor Analysis: Therapeutic Proteins ... http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical   ...   The new Competitive ...
Breaking Biology Technology:Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8
... Inc., a biotechnology company delivering breakthrough therapies in central ... will be participating at two upcoming healthcare investor conferences. ... at the 2nd Annual BIO Venture Conference on April ... Hotel in Boston, MA. On April 9 at 11:30 ...
... Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; ... generation of monoclonal antibodies based on its Dynamic Cross ... Company has entered into a loan facility with a ... to USD$2.5 million. The loan facility, subject to final ...
... March 25 Human Genome Sciences, Inc. (Nasdaq: ... subsidiary of Eisai Corporation of North America, today ... to discover, develop and commercialize therapeutic monoclonal antibodies ... specifically target antigens discovered by HGS.(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ...
Cached Biology Technology:Accera, Inc. to Present at Upcoming Investor Conferences 2InNexus Biotechnology Announces a Loan Facility of up to USD$2.5 Million 2Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 2Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 3Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 4Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology 5
(Date:5/16/2013)... scientists have shown a gene involved in neurodegenerative disease ... of the circadian clock. , In a study ... gene, called Ataxin-2, keeps the clock responsible for sleeping ... the rhythm of the fruit fly,s sleep-wake cycle is ... for the fly. , The discovery is particularly ...
(Date:5/16/2013)... 16, 2013 Integrated Biometrics patented LES ... custom thin film transistor camera introduces Sherlock, a ... image in the smallest and lightest form factor ... F Mobile ID FAP 45, Certified scanner is ... size and weight when compared to optical scanners. ...
(Date:5/16/2013)... neuroscientists from Canada and around the world are ... Canadian Neuroscience Meeting will showcase the latest in ... and reveal clues to understanding the disorders that ... research, and this meeting will showcase the best ... world," says Sam David, President of the Canadian ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
... could create an evolutionary express lane that leads to the ... Pittsburgh and the University of Wisconsin at Madison have found. ... National Academy of Sciences ( PNAS ) that slight ... the when, where, and how much in gene productioncan activate ...
... University study has found that sunlight decreases the toxicity of ... United States every year. While golden algae is primarily ... and lakes, including Lake Whitney and Lake Waco in Central ... several environmental factors influence toxin production, but new research from ...
... Alexandria, VA The International and American Associations for ... symposium themed "Tissue Injury and Pulp Regeneration," held in ... the IADR Pulp Biology and Regeneration Group, and they ... Advances in Dental Research, an E-supplement to the ...
Cached Biology News:Leaky genes put evolution on the fast track, Pitt and UW-Madison researchers find 2IADR/AADR publish proceedings from Symposium on Tissue Injury and Pulp Regeneration 2
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
Topoisomerase I...
...
Biology Products: